Table 4.
Therapies | Role in response | miRNA | Putative targets | Agent | Biological samples | Refs. |
---|---|---|---|---|---|---|
Hormone therapy | ||||||
Antiestrogens | Sensitivity | miR-342 | CCNB1 | Tamoxifen | Cell lines and tumor tissues | [149] |
miR-26a | EZH2 | Tumor tissues | [150] | |||
miR-30c | EGFR | [147] | ||||
miR-10, -126 | – | [151] | ||||
Resistance | miR-221/222 | CDKN1B | Tamoxifen, fulvestrant | Tumor tissues and cell lines | [152, 153] | |
miR-519a | CDKN1B PTEN, RB1 | Tamoxifen | Tumor tissues and cell lines | [154] | ||
miR-155 | SOCS6 | [131] | ||||
miR-210 | – | Tumor tissues | [110] | |||
miR-301 | FOXF2, BBC3, PTEN, COL2A1 | Tumor tissues, cell lines and xenografts | [94] | |||
Aromatase inhibitors | Sensitivity | miR-125b let-7c | ERBB2 | Letrozole, anastrozole | Tumor tissues and cell lines | [116] |
Resistance | miR-181a | BCL2L11 | Letrozole | Cell lines, xenografts and tumor tissues | [155] | |
Antibodies | Sensitivity | miR-210 | – | Trastuzumab | Cell lines and plasma | [148] |
Resistance | miR-21 | PTEN | Trastuzumab | Cell lines, xenograft and tumor tissues | [156] | |
Chemotherapy | Sensitivity | miR-451 | MRP-1 | Doxorubicin | Cell lines and tumor tissues | [157] |
miR-200c | MRP-1 | [158] | ||||
miR-134 | ABCC1 | [159] | ||||
miR-128 | BMI1, ABCC5 | Doxorubicin, Paclitaxel | Cell lines, xenografts and tumor tissues | [121] | ||
miR-100 | MTOR | Paclitaxel | Cell lines, xenografts and luminal tumor tissues | [119] | ||
miR-16 | IKBKB | Cell lines and tumor tissues | [160] | |||
miR-621 | FBXO11 | Paclitaxel + Carboplatin | Cell lines, xenografts and tumor tissues | [161] | ||
Resistance | miR-125b | BAK1, E2F3 | FEC | Cell lines, tumor tissues and serum | [162] | |
miR-141 | − | Taxane, Anthracyclines | Cell lines and tumor tissues | [163] | ||
miR-221 | CDKN1B | Plasma | [164] | |||
miR-155 | FOXO3a | Paclitaxel, VP-16, Doxorubicin | Cell lines and tumor tissues | [165] | ||
Radiotherapy | Sensitivity | miR-155 | RAD51 | – | Cell lines and TNBC tissues | [166] |
CCNB1 cyclin B1, EZH2 enhancer of zeste homolog 2, EGFR epidermal growth factor receptor, CDKN1B cyclin-dependent kinase inhibitor 1B, PTEN phosphatase and tensin homolog, RB1 retinoblastoma 1, SOCS6 suppressor of cytokine signaling 6, FOXF2 forkhead box F2, BBC3 BCL2 binding component 3, COL2A1 collagen type II alpha 1, ERBB2 Erb-B2 receptor tyrosine kinase 2, BCL2L11 Bcl-2-like protein 11, MRP1 multidrug resistance-associated protein 1, ABCC1 ATP binding cassette subfamily C member 1, BMI1 BMI1 polycomb ring finger oncogene, ABCC5 ATP binding cassette subfamily C member 5, MTOR mechanistic target of rapamycin, IKBKB IκB kinase β, FBXO11 F-box protein 11, BAK1 BCL2 antagonist/killer 1, E3F3 E2F transcription factor 3, FOXO3a Forkhead box O3a, RAD51 RAD51 recombinase, FEC 5-florouracil, epirubucin and cyclophosphamide